Komori
Japan Medical Dynamic Marketing (7600) · FactProprietary products accounted for a lower proportion of salesLatest Earnings (2026-07-30): "Advanced"

Higher proportion of sales from proprietary products

First written in FY2016. 9 of 27 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-07-30.

27entries
11years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2017-Q1 – FY2018-Q3OtherFY2019-Q1 – FY20242016: 320162017: 420172018: 320182019: 320192020: 320202021: 320212022: 020222023: 220232024: 320242025: 120252026: 22026
Same theme, other companies
Improving the Product Mix and Profitability by Increasing the Own-Brand RatioA theme 12 companies write about · 1 as a headwind · 12 as a tailwind

The whole theme swung hardest in 2023: 1 of 6 companies on the "Worse" side.

4 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  2. FY2026-H1Proprietary products accounted for a lower proportion of salesAnnual report

    「The proportion of proprietary products in consolidated sales was 79.6%, compared with 80.9% in the same period of the previous year.」

    The proportion of revenue from proprietary products fell 1.3 percentage points year on year to 79.6%.
  3. FY2025-H1AdvancedAnnual report

    「The proportion of proprietary products in consolidated sales was 80.9%, compared with 80.1% in the same period of the previous year.」

    The proportion of revenue from proprietary products rose 0.8 percentage points year on year to 80.9%.
  4. FY2024Proprietary products accounted for a lower proportion of salesAnnual report

    「The proportion of proprietary products in consolidated sales was 80.2%, compared with 80.6% in the previous consolidated fiscal year.」

    The proportion of proprietary products in sales declined from 80.6% in the previous year to 80.2%.
  5. FY2024-Q3The proportion of proprietary products in sales declined year on yearAnnual report

    「The proportion of proprietary products in consolidated sales was 80.3%, compared with 80.8% in the same quarter of the previous year.」

    The proportion of revenue from proprietary products fell 0.5 percentage points year on year to 80.3%.
  6. FY2024-Q2The proportion of proprietary products in sales declined year on yearAnnual report

    「The proportion of proprietary products in consolidated sales was 80.1%, compared with 80.3% in the same quarter of the previous year.」

    The proportion of proprietary products in sales declined from 80.3% in the same quarter of the previous year to 80.1%.
  7. FY2024-Q1The proportion of proprietary products in sales was flat year on yearAnnual report

    「The proportion of proprietary products in consolidated sales was 80.1%, unchanged from 80.1% in the same quarter of the previous year.」

    Proprietary products accounted for 80.1% of sales, at the same level as in the same quarter of the previous year.
  8. FY2022-Q2The lower proprietary-product sales mix and deterioration in the cost ratio continuedAnnual report

    「Proprietary products accounted for 79.6% of sales due to the recovery in US sales and other factors, while the cost of sales ratio was 32.2%, compared with 32.0% in the same quarter of the previous year, due to exchange-rate fluctuations and other factors.」

    The proportion of revenue from proprietary products was 79.6%, and the cost-of-sales ratio rose from 32.0% in the same period a year earlier to 32.2%.
  9. FY2022-Q1The proprietary-product sales mix declined, but the cost of sales ratio improved slightlyAnnual report

    「Due to the recovery in US sales and other factors, proprietary products accounted for 80.1% of sales, and the cost of sales ratio was 32.0%, compared with 32.3% in the same quarter of the previous year.」

    The proportion of revenue from proprietary products declined from 83.3% in the same period a year earlier to 80.1%, while the cost-of-sales ratio edged down from 32.3% to 32.0%.
  10. FY2021-Q3Decline in the proportion of revenue from proprietary products and deterioration in the cost ratio continuedAnnual report

    「The proportion of proprietary products in sales declined due to lower US sales and other factors related to the impact of COVID-19, worsening the cost of sales ratio to 31.9%, from 28.6% in the same quarter of the previous year.」

    The continuing decline in the proportion of revenue from proprietary products was again cited as a factor behind the deterioration in the cost ratio, and the cost-of-sales ratio rose year on year.
  11. FY2021-Q2Continued decline in the proportion of revenue from proprietary products worsened the cost ratioAnnual report

    「Cost of sales was affected by factors including the decline in the proportion of proprietary products in sales, which worsened the cost of sales ratio. The cost of sales ratio was 32.0%, compared with 28.9% in the same quarter of the previous year.」

    The proportion of revenue from proprietary products continued to decline, and the cost-of-sales ratio deteriorated from 28.9% in the same period a year earlier to 32.0%.
  12. FY2021-Q1Continued decline in the proportion of revenue from proprietary products worsened the cost ratioAnnual report

    「Cost of sales was affected by factors including the decline in the proportion of proprietary products in sales, which worsened the cost of sales ratio. The cost of sales ratio was 32.3%, compared with 29.0% in the same quarter of the previous year.」

    The proportion of revenue from proprietary products continued to decline, and the cost-of-sales ratio deteriorated from 29.0% in the same period a year earlier to 32.3%.
  13. FY2020Decline in the proportion of revenue from proprietary products continuedAnnual report

    「Although the gradual reduction of reimbursement prices in Japan and the decline in the proportion of proprietary products in sales contributed to deterioration in the cost of sales ratio, lower manufacturing costs resulting from expanded in-house manufacturing capacity at the US subsidiary and increased overseas sourcing, among other factors, reduced the cost of sales ratio to 29.2%, from 29.4% in the previous consolidated fiscal year.」

    While the decline in the proportion of revenue from proprietary products was cited as a factor behind the deterioration in the cost ratio, the overall cost ratio improved due to expanded in-house manufacturing capacity and increased overseas sourcing.
  14. FY2020-Q2Proprietary products accounted for a lower proportion of salesAnnual report

    「Although the proportion of proprietary products in sales declined to 83.0%, from 87.6% in the same quarter of the previous year, the cost of sales ratio was 28.9%, compared with 29.0%, due to lower manufacturing costs resulting from expanded in-house manufacturing capacity at the US subsidiary and increased overseas sourcing, among other factors.」

    The proportion of revenue from proprietary products declined from 87.6% in the same quarter a year earlier to 83.0%.
  15. FY2020-Q1Proprietary products accounted for a lower proportion of salesAnnual report

    「Despite the cost reductions achieved through expanded in-house manufacturing capacity in North America and stronger overseas procurement, the cost of sales ratio was 29.0%, compared with 28.4% in the same quarter of the previous year, due to the decline in the proportion of revenue from proprietary products to 83.3% from 88.0% and the impact of reimbursement price reductions.」

    The proportion of revenue from proprietary products declined from 88.0% in the same quarter a year earlier to 83.3%.
  16. FY2019-Q3Proprietary products accounted for a lower proportion of salesAnnual report

    「The cost of sales ratio was 29.3%, compared with 27.6% in the same quarter of the previous year, due to the decline in the proportion of proprietary products in sales to 86.6%, from 89.2%, and the impact of lower reimbursement prices.」

    The proportion of revenue from proprietary products declined from 89.2% in the same quarter a year earlier to 86.6%.
  17. FY2019-Q2Proprietary products accounted for a lower proportion of salesAnnual report

    「The cost of sales ratio was 29.0%, compared with 27.5% in the same quarter of the previous year, due to the decline in the proportion of proprietary products in sales to 87.6%, from 89.4%, and the impact of lower reimbursement prices.」

    The proportion of revenue from proprietary products declined from 89.4% in the same quarter a year earlier to 87.6%.
  18. FY2019-Q1Proprietary products accounted for a lower proportion of salesAnnual report

    「The cost of sales ratio was 28.4%, compared with 27.5% in the same quarter of the previous year, due to the decline in the proportion of proprietary products in sales to 88.0%, from 89.7%, and the impact of lower reimbursement prices.」

    The proportion of revenue from proprietary products declined from 89.7% in the same quarter a year earlier to 88.0%.
  19. FY2018-Q3AdvancedAnnual report

    「Despite the impact of the weaker yen and lower reimbursement prices, the cost of sales ratio improved to 27.6%, from 27.8% in the same quarter of the previous year, due to lower manufacturing costs and the increase in the proportion of proprietary products in sales to 89.2%, from 87.5%.」

    The proportion of revenue from proprietary products rose from 87.5% in the same quarter a year earlier to 89.2%.
  20. FY2018-Q2AdvancedAnnual report

    「Despite the impact of the weaker yen and lower reimbursement prices, the cost of sales ratio improved to 27.5%, from 27.9% in the same quarter of the previous year, due to lower manufacturing costs and the increase in the proportion of proprietary products in sales to 89.4%, from 87.3%.」

    The proportion of revenue from proprietary products rose from 87.3% in the same period a year earlier to 89.4%.
  21. FY2018-Q1AdvancedAnnual report

    「As a result, despite lower reimbursement prices, the cost of sales ratio improved to 27.5% (29.3% in the same quarter of the previous year), reflecting the effect of lower manufacturing costs and the rise in the ratio of sales from proprietary products to 89.7% (87.1% in the same quarter of the previous year).」

    The proportion of revenue from proprietary products rose from 87.1% in the same period a year earlier to 89.7%, while the cost-of-sales ratio improved from 29.3% to 27.5%.
  22. FY2017AdvancedAnnual report

    「Despite the reduction in redemption prices, the proportion of revenue from proprietary products rose to 87.5%, compared with 85.1% in the previous consolidated fiscal year. Together with the impact of yen appreciation and other factors, this improved the cost-of-sales ratio to 28.8% from 29.3%.」

    For the full year, the proportion of revenue from proprietary products rose from 85.1% to 87.5%, and the cost-of-sales ratio also improved.
  23. FY2017-Q3AdvancedAnnual report

    「As a result, the ratio of sales from proprietary products rose to 87.5% (85.1% in the same quarter of the previous year), and the cost of sales ratio was 27.8% (29.0% in the same quarter of the previous year), despite a reduction in reimbursement prices, partly due to the stronger yen and other factors.」

    The proportion of revenue from proprietary products rose from 85.1% to 87.5%.
  24. FY2017-Q2AdvancedAnnual report

    「As a result, proprietary products accounted for 87.3% of sales, up from 85.0% in the same quarter of the previous year.」

    The proportion of proprietary products in sales rose from 85.0% in the same quarter of the previous year to 87.3%.
  25. FY2017-Q1AdvancedAnnual report

    「As a result, proprietary products accounted for 87.1% of sales, up from 84.0% in the same quarter of the previous year.」

    The proportion of revenue from proprietary products rose from 84.0% to 87.1%.
  26. FY2016First statedAnnual report

    「As a result, the proportion of revenue from proprietary products rose to 85.1%, compared with 80.0% in the previous consolidated fiscal year, and despite the impact of yen depreciation and other factors, the cost-of-sales ratio declined to 29.3% from 30.1%.」

    The proportion of revenue from proprietary products rose from 80.0% to 85.1%, while the cost-of-sales ratio declined from 30.1% to 29.3%.
Moved together

"Expansion of the North American Business and Development of the Overseas Trading Business" moved the same way as this thread, in the same document, in 8 of its 27 moves.

888754★123456
  1. ★This thread
  2. 1Expansion of the North American Business and Development of the Overseas Trading Business8×
  3. 2Increasing the proportion of revenue from proprietary products and in-house manufacturing capacity8×
  4. 3Expansion of North American sales and the impact of new customers and new products8×
  5. 4Return to Revenue and Profit Growth7×
  6. 5Maintaining profitable high growth in Japan and North America while balancing growth and efficiency5×
  7. 6Cost Efficiency Through Expanded In-House Manufacturing and Operational Reform4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Japan Medical Dynamic Marketing's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Earnings of 2026-07-30: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Higher proportion of sales from proprietary products | Japan Medical Dynamic Marketing,INC. (7600) | Komori